A US Food and Drug Administration panel’s review of two opioid-containing products on 15 January suggests sponsors face a high bar in bringing new formulations to market under the agency’s emerging benefit/risk framework for the category.
The anesthetic and analgesic drug products and drug safety and risk management advisory committees overwhelmingly recommended against approval of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?